Ginkgo Bioworks Holdings, Inc. Class A Common Stock (DNA)
13.52
-0.73 (-5.12%)
Ginkgo Bioworks is a biotechnology company that focuses on the design and engineering of microbial strains for various applications across diverse industries, including pharmaceuticals, agriculture, and industrial biotechnology
By leveraging advanced genetic engineering and synthetic biology techniques, Ginkgo aims to create custom organisms that can produce valuable ingredients, enhance agricultural yields, or contribute to sustainable manufacturing processes. The company operates through a platform model, allowing collaborations with partners to transform biological systems into efficient and scalable solutions that address real-world challenges, all while paving the way for a future with more sustainable and tailored biological products.
![](https://cdn.benzinga.com/files/images/story/2025/02/06/Movers-Stocks.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · February 6, 2025
![](/next-assets/images/schema-image-default.png)
Via Benzinga · November 11, 2024
![](https://cdn.benzinga.com/files/images/story/2024/09/18/DNA-CRISPR-CSPR.jpeg?width=1200&height=800&fit=crop)
Ginkgo Bioworks Holdings Inc (NYSEDNA) shares continue to trade higher after rising nearly 10% on Tuesday. Here's a look at what's going on.
Via Benzinga · September 18, 2024
![](https://g.foolcdn.com/editorial/images/791073/person-in-a-lab-looking-through-a-microscope.jpg)
The company is forging ahead with next-generation drug development solutions.
Via The Motley Fool · September 17, 2024
![](https://cdn.benzinga.com/files/images/story/2024/09/17/Medicine-Doctor-Touching-Electronic-Medi_0.jpeg?width=1200&height=800&fit=crop)
Ginkgo Bioworks introduces a protein large language model and API, developed with Google Cloud, to streamline drug discovery by leveraging AI and proprietary biological data, offering affordable and accessible tools for researchers.
Via Benzinga · September 17, 2024
![](https://cdn.benzinga.com/files/images/story/2024/09/17/Medicine-Doctor-Touching-Electronic-Medi.jpeg?width=1200&height=800&fit=crop)
Ginkgo Bioworks Holdings Inc (NYSEDNA) shares are surging Tuesday after the company announced the launch of its new protein large language model (LLM) built on Google Cloud.
Via Benzinga · September 17, 2024
![](https://cdn.benzinga.com/files/images/story/2024/09/17/movers-image_1.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · September 17, 2024
![](https://g.foolcdn.com/editorial/images/789237/frustrated-investor-looking-at-stocks.jpg)
Could this beaten-down stock turn things around in the near future?
Via The Motley Fool · September 5, 2024
![](https://g.foolcdn.com/editorial/images/789209/chemist-team-looking-beaker-of-green-chemical.jpg)
The risks may resolve in a year or so but seizing the opportunities will take longer.
Via The Motley Fool · September 3, 2024
![](https://g.foolcdn.com/editorial/images/789105/scientist-peers-in-microscope-in-lab.jpg)
The company is using artificial intelligence, and planning to help others use AI empowered by its data collection.
Via The Motley Fool · September 2, 2024
![](https://g.foolcdn.com/editorial/images/787935/scientist-configures-tilting-machine.jpg)
Its ambitious business model may not be sustainable.
Via The Motley Fool · August 24, 2024
![](https://g.foolcdn.com/editorial/images/787159/coffee-shop-investor-getty.jpg)
Have shares of the troubled life sciences business fallen too far?
Via The Motley Fool · August 15, 2024
![](https://g.foolcdn.com/editorial/images/785970/biotech-pharma-researchers-talk-lab.jpg)
Efficiency in core processes is set to increase substantially due to AI.
Via The Motley Fool · August 13, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
DNA stock results show that Ginkgo Bioworks Holdings missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 8, 2024
![](https://investorplace.com/wp-content/uploads/2022/02/dna-helix.png)
Ginkgo Bioworks stock is falling hard on Friday as DNA investors prepare to vote on a reverse stock split later this month.
Via InvestorPlace · August 2, 2024
![](https://investorplace.com/wp-content/uploads/2022/06/meme-stocks-reddit-wall-street-bets-1600.png)
Which of these 7 meme stocks are likely to punish investors and which are likely to provide free money? Read on to see.
Via InvestorPlace · July 23, 2024
![](https://investorplace.com/wp-content/uploads/2019/07/sell-chalk-board.jpg)
Biotech stocks can be extremely challenging because it takes a long time to bring a therapy to market. Here are some biotech stocks to sell.
Via InvestorPlace · July 22, 2024
![](https://investorplace.com/wp-content/uploads/2020/08/genetics-dna-flgt-1600.jpg)
Ginkgo Bioworks has multiple, positive catalysts that can make the low valuation of Ginkgo Bioworks stock melt up.
Via InvestorPlace · July 18, 2024
![](https://investorplace.com/wp-content/uploads/2022/08/dna_ginkobioworks1600.png)
Although Ginkgo Bioworks’ partnership with an agricultural innovator boosted DNA stock, the company still faces challenges.
Via InvestorPlace · July 16, 2024
![](https://g.foolcdn.com/editorial/images/783060/two-scientists-review-data-in-lab-bench.jpg)
A recovery plan is underway, but it isn't a slam dunk.
Via The Motley Fool · July 14, 2024
![](https://investorplace.com/wp-content/uploads/2020/09/avoid1600_c.jpg)
Avoid these three stocks like the plague in 2024 to protect your portfolio from potential pitfalls and losses.
Via InvestorPlace · July 11, 2024
![](https://investorplace.com/wp-content/uploads/2021/12/penny-stocks-1600.jpg)
These high-risk penny stocks may be cheap, but their low per-share pricing conceals unique tailwinds that could propel them higher.
Via InvestorPlace · July 10, 2024
![](https://investorplace.com/wp-content/uploads/2022/08/dna_ginkobioworks1600.png)
Ginkgo Bioworks stock is down, but this doesn't mean it's a bargain as Ginkgo Bioworks faces a serious delisting threat.
Via InvestorPlace · July 10, 2024